WuXi AppTec frees up money for Middle East push
The drugs services giant has stepped up sales of non-core Chinese assets to concentrate on its international expansion, with plans for a base in Saudi Arabia Key Takeaways: The company…
BRIEF: WuXi XDC to raise $348 million via share placements at 4% discount
Contract drug services provider WuXi XDC Cayman Inc. (2268.HK) on Wednesday announced two share placements to raise a combined HK$2.71 billion ($348 million) in new funds. The company plans to…
Rising profit at WuXi Biologics underscores drug sector rebound
The provider of pharmaceutical services has joined other flagship companies in the WuXi group in projecting stronger first-half earnings after a couple of lean years Key Takeaways: WuXi Biologics expects…
Fortune smiles again on WuXi AppTec with profit surge
The drug services giant has forecast a jump in revenue for the first half and a doubling of net profit, after U.S. policy concerns abated Key Takeaways: The projected results…
WuXi group wrestles with uncertainty over pharma tariffs
Drugs services giant WuXi AppTec cashed in a stake in Wuxi XDC to soften the blow from a first round of Trump tariffs, as the pharma sector braces for another…
BRIEF: WuXi XDC’s revenue, profit jump in 2024
WuXi XDC Cayman Inc. (2268.HK), a provider of contract services for drug companies, said on Wednesday its revenue and profit rose sharply last year on strong demand for services related…
U.S. rethinks timing of biotech crackdown, easing pressure on WuXi family
The latest draft of a U.S. biosecurity law would give drug companies until 2032 to cut their ties with Chinese contract suppliers, allowing WuXi companies time to focus on Europe…